In a statement, Merck said an analysis of real-world data from an Israeli study, known as Clalit, showed that Lagevrio reduced hospitalisations and deaths due to COVID-19 in patients 65 years and ...

Merck & Co has said it will ask the EMA’s human medicines committee (CHMP) to look again at a decision not to recommend approval of its antiviral Lagevrio for treating some people with COVID-19.

Sales of Merck's Covid antiviral pill, Lagevrio, also fell 40% to $383 million during the quarter. Still, that topped ...

The United Kingdom conditionally approved molnupiravir, branded as Lagevrio, earlier this month. Merck expects to produce 10 million courses of the treatment by the end of this year, with at least ...

and lower sales of COVID antiviral Lagevrio. Outside of China, Gardasil sales grew by double-digits in almost every major ...

Merck reported adjusted earnings of $1.72 per ... Supply constraints in China also hurt sales. Sales of Lagevrio (molnupiravir) declined 37% to $121 million in the quarter.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...